
Please visit answersincme.com/860/99505211-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in psoriasis discuss real‑world strategies for using oral small molecules in moderate to severe disease. Upon completion of this activity, participants should be better able to: Identify patients with moderate to severe plaque psoriasis who would benefit from oral small molecule therapy; Differentiate the targets/mechanisms of action of available oral small molecule therapy for moderate to severe plaque psoriasis; and Integrate strategies to individualize oral small molecule therapy for moderate to severe plaque psoriasis, while balancing safety, considering regional barriers.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis

From Burden to Breakthrough: The Rise of KIT D816V-Selective Therapy in Indolent Systemic Mastocytosis

Small Molecules, Big Decisions: Where Do TYK2 Inhibitors Fit in Psoriasis Treatment?

The Psoriatic Disease Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape
Free AI-powered recaps of CME in Minutes: Education in Dermatology and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.